Questions from shareholders: comment on share pric
Post# of 72440
Leo: can't comment directly, but share price isn't always an accurate reflection of a company's potential. He's confident in value of assets for shareholders and patients. Incredible pipeline, 2 first-in-class drugs. Trials have short timeline till results. Should increase visibility of the company.
Partnerships: is there 1 drug most likely to be partnered? Outright acquisition of the company?
Partnering is primary goal. Need to get pipeline far enough along to present data to SEVERAL potential partners. Some companies want one drug, others want the whole thing. Will keep open mind about deals. Big pharma knows there is tremendous value in our pipeline. Data will start coming in soon.
Still looking for uplist to Nasdaq etc? What is timeline?
Intend to uplist. Part of strategic plan. Leverage pipeline with successful trial results or partnerships.
Clinical questions:
Bril and IBD? Dr. B: we're extremely excited, non-biologic non-steroid. Have posted strong interim data so far.